{
  "id": 12417111,
  "title": "ArriVent collapses on disappointing lung cancer data",
  "url": "https://urgent.news/2026/10/06/arrivent-collapses-on-disappointing-lung-cancer-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-06T16:12:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/arrivent-furmonertinib-egfr-lung-cancer-study-results/832220/"
  },
  "original_language": "en",
  "account": null,
  "summary": "More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks",
        "url": "https://urgent.news/2026/10/06/arrivents-lung-cancer-drug-firmonertinib-fails-key-late-stage-trial",
        "published": "2026-10-06T14:47:37.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}